Over four years of treatment with Orlistat in the XENDOS study, the risk of developing diabetes was found to be 37.3% lower compared to placebo (P = 0.0032) (Torgerson et al 2004). In the 21% of subjects that had impaired glucose tolerance at baseline, the incidence of diabetes over the 4 years was decreased by 45.0% with Orlistat therapy. This finding has been supported by a more recent RCT which showed that the incidence of new type-2 diabetes was significantly decreased in patients using Orlistat for weight maintenance after initial weight loss (8/153 new cases type-2 diabetes vs 17/156 cases, P = 0.041) (Richelsen et al 2007).